Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Schenk

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2012
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitroErin L Schenk, Brian D Koh, Karen S Flatten, et al.
Clinical Lung Cancer|October 9, 2024
Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung CancerAlexander S Watson, Harris B Krause, Andrew Elliott, et al.
Cancer|January 22, 2008
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study resultsNigel J Bundred, Ian D Campbell, Neville Davidson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2021
Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor MicroenvironmentAmber M Johnson, Jennifer M Boland, Julia Wrobel, et al.
Cell Death and Differentiation|July 25, 2021
Absence of pro-survival A1 has no impact on inflammatory cell survival in vivo during acute lung inflammation and peritonitisLahiru Gangoda, Robyn L Schenk, Sarah A Best, et al.
Frontiers in Immunology|September 14, 2018
GM-CSF Quantity Has a Selective Effect on Granulocytic vs. Monocytic Myeloid Development and FunctionLi Sun, Jai Rautela, Rebecca B Delconte, et al.
Cell Death and Differentiation|January 14, 2017
Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartmentRobyn L Schenk, Selma Tuzlak, Emma M Carrington, et al.
NPJ Precision Oncology|January 23, 2023
Evolution of acquired resistance in a ROS1<sup>+</sup> KRAS G12C<sup>+</sup> NSCLC through the MAPK pathwayKatherine Priest, Anh Le, Amanuail Gebregzabheir, et al.
Science Signaling|November 25, 2025
SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in <i>EGFR</i>-mutant lung cancerBrianna R Daley, Patricia L Theard, Jacob M Hughes, et al.
Clinical Lung Cancer|December 21, 2019
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung CancerTejas Patil, Rao Mushtaq, Sydney Marsh, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2012
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitroErin L Schenk, Brian D Koh, Karen S Flatten, et al.
Clinical Lung Cancer|October 9, 2024
Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung CancerAlexander S Watson, Harris B Krause, Andrew Elliott, et al.
Cancer|January 22, 2008
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study resultsNigel J Bundred, Ian D Campbell, Neville Davidson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2021
Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor MicroenvironmentAmber M Johnson, Jennifer M Boland, Julia Wrobel, et al.
Cell Death and Differentiation|July 25, 2021
Absence of pro-survival A1 has no impact on inflammatory cell survival in vivo during acute lung inflammation and peritonitisLahiru Gangoda, Robyn L Schenk, Sarah A Best, et al.
Frontiers in Immunology|September 14, 2018
GM-CSF Quantity Has a Selective Effect on Granulocytic vs. Monocytic Myeloid Development and FunctionLi Sun, Jai Rautela, Rebecca B Delconte, et al.
Cell Death and Differentiation|January 14, 2017
Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartmentRobyn L Schenk, Selma Tuzlak, Emma M Carrington, et al.
NPJ Precision Oncology|January 23, 2023
Evolution of acquired resistance in a ROS1<sup>+</sup> KRAS G12C<sup>+</sup> NSCLC through the MAPK pathwayKatherine Priest, Anh Le, Amanuail Gebregzabheir, et al.
Science Signaling|November 25, 2025
SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in <i>EGFR</i>-mutant lung cancerBrianna R Daley, Patricia L Theard, Jacob M Hughes, et al.
Clinical Lung Cancer|December 21, 2019
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung CancerTejas Patil, Rao Mushtaq, Sydney Marsh, et al.
Pageof 11